Iranian Journal of Nuclear Medicine

Iranian Journal of Nuclear Medicine

Pulmonary lymphangitic carcinomatosis as a rare occurrence in prostate cancer: Findings on [99mTc]Tc-PSMA and [177Lu]Lu-PSMA scintigraphy

Articles in Press

Document Type : Case Report

Authors
Alireza Gholami 1
Fatemeh Taheri 2
Emran Askari 2
Hamidreza Ghorbani 3, 4
Amin Saber Tanha 2
1 Department of Medical Physics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2 Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
3 Department of Urology, Imam Reza hospital, Mashhad University of Medical Sciences, Mashhad, Iran
4 Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran
10.22034/irjnm.2026.130616.1779
Abstract
This report describes a patient with prostate cancer who demonstrated bilateral pulmonary lymphangitic carcinomatosis (PLC) identified on [99mTc]Tc‑prostate-specific membrane antigen (PSMA) imaging. A 77-year-old man with significantly high PSA levels, extensive skeletal and lymph node metastases, received standard androgen deprivation therapy (ADT) and [177Lu]Lu-PSMA radioligand therapy, in addition to palliative care for lung involvement. In spite of these treatments, his clinical condition deteriorated rapidly and he exhibited no significant response to the therapy. This case illustrates a rare occurrence of lymphangitic carcinomatosis in a patient with prostate cancer who presented with no respiratory symptoms.
Keywords
Radio-ligand therapy
Theranostics
SPECT/CT
Pulmonary metastasis
Castration resistance
Subjects
  1. Ramos-Laguna KA, West W, El-Baba F, Ponce-Zepeda J, Chan P, Lindgren B, Chang CF. Pulmonary lymphangitic carcinomatosis from metastatic prostate carcinoma initially presenting as interstitial lung disease and dyspnea. Chest. 2024;166(4):A5423–4.
  2. Lindell MM, Doubleday LC, von Eschenbach AC, Libshitz HI. Mediastinal metastases from prostatic carcinoma. J Urol. 1982;128(2):331–3.
  3. Klimek M. Pulmonary lymphangitis carcinomatosis: systematic review and meta-analysis of case reports, 1970-2018. Postgrad Med. 2019;131(5):309–18.
  4. Bruce D, Heys S, Eremin O. Lymphangitis carcinomatosa: a literature review. J R Coll Surg Edinb. 1996;41(1):7–13.
  5. Lin RJ, Adelman RD, Mehta SS. Dyspnea in palliative care: expanding the role of corticosteroids. J Palliat Med. 2012;15(7):834–7.
  6. Gilchrist F, Alton H, Brundler M, Edwards L, Plunkett A, Rao S. Pulmonary lymphangitic carcinomatosis presenting as severe interstitial lung disease in a 15-year-old female. Eur Respir Rev. 2011;20(121):208–10.
  7. Soares FA, Pinto A, Landell G, De Oliveira J. Pulmonary tumor embolism to arterial vessels and carcinomatous lymphangitis. A comparative clinicopathological study. Arch Pathol Lab Med. 1993 Aug;117(8):827-31.
  8. Fabozzi SJ, Schellhammer PF, El‐Mahdi AM. Pulmonary metastases from prostate cancer. Cancer. 1995;75(11):2706–9.
  9. Moreau A, Tabutin M, Bouhamama A, Kryza D. A Rare Atypical intrapericardial prostate adenocarcinoma metastasis with 68Ga-PSMA-11 PET/CT. Clin Nucl Med. 2024;49(12):1130-1132.
  10. Tang VD, Campbell P, Pattison DA. Lymphangitic carcinomatosis from prostate cancer identified with gallium-68 prostate-specific membrane antigen positron emission tomography imaging. Urology. 2018;114:e1–e2.
  11. Aggarwal P, Satapathy S, Sood A, Singh P, Singh H, Chopra S, Prakash G , Mittal BR. Recurrent pulmonary lymphangitis carcinomatosis detected on 177Lu-PSMA-617 post-therapy scan in mCRPC with negative PSMA PET and HRCT. Eur J Nucl Med Mol Imaging. 2026;53(3):1365-1366..
  12. Raeisi N, Aghaee A, Aryana K, Soltani S, Ghorbani H. 99mTc-PSMA and 99mTc-FAPI-46 Uptake in Pulmonary Lymphangitic Carcinomatosis: A Rare Form of Metastasis in Prostate Cancer Patient, Responding to Modified Treatments. Clin Nucl Med. 2024;49(12):e691-e692.
  13. Zukotynski KA, Jadvar H, Potvin K, Cho SY, Kim CK, Winquist E. Prostate Cancer Lymphangitic Pulmonary Carcinomatosis: Appearance on: 18: F-FDG PET/CT and: 18: F-DCFPyL PET/CT. Clin Nucl Med. 2020;45(9):727–9.
  14. Liu BL, Hong JJ, Tang K, Lin J, Zheng XW. 18F-PSMA-1007 uptake in pulmonary lymphangitic carcinomatosis metastasis from prostate cancer. Clin Nucl Med. 2021;46(7):e355–7.
  15. Dondi F, Bellini P, Cossandi M, Camoni L, Rinaldi R, Viganò GL, Bertagna F. The Role of [18F] FDG PET Imaging for the Assessment of Pulmonary Lymphangitic Carcinomatosis: A Comprehensive Narrative Literature Review. Diagnostics (Basel). 2025;15(13):1626..
  16. Bouchelouche K, Vendelbo MH. Pulmonary opacities and bronchiectasis avid on 68Ga-PSMA PET. Clin Nucl Med. 2017;42(4):e216–7.
  17. Park Y-J, Im Y, Kwon OJ, Han J, Ahn M-J, Kim J, Um SW , Choi JY. Prognostic value of pretherapeutic FDG PET/CT in non-small cell lung cancer with pulmonary lymphangitic carcinomatosis. Sci Rep. 2023;13(1):345.
  18. Wang JS, Wong T, Wu KA, Mullikin TC, Armstrong A. Diffuse pneumonitis after Lutetium-177-PSMA-617 treatment in a patient with metastatic castration-resistant prostate cancer. BMJ Case Rep. 2024;17(2):e257772.
Iranian Journal of Nuclear Medicine

Articles in Press, Accepted Manuscript
Available Online from 08 August 2026